Zhongguo linchuang yanjiu (Mar 2024)
Dapagliflozin combined with sitagliptin in treatment of type 2 diabetes
Abstract
Objective To investigate the efficacy of single drug treatment of dapagliflozin and combination of dapagliflozin and sitagliptin in the treatment of type 2 diabetes mellitus (T2DM). Methods Sixty-two patients with T2DM admitted to Luhe District Hospital of Chinese Medicine from January 2022 to December 2023 were selected as research subjects, and the patients were randomly divided into two groups, with 31 cases in each group. The control group only received treatment with dapagliflozin (10 mg/d oral), while the observation group received both dapagliflozin (10 mg/d oral) and sitagliptin (100 mg/d oral) treatment. Both groups were treated for 3 months. The post-treatment blood glucose control effects ［fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c)］, blood glucose fluctuations, inflammatory markers ［C-reactive protein (CRP)］, and cardiac function ［left ventricular ejection fraction (LVEF)］ were compared between two groups. Results After 3 months of treatment, compared with before treatment, both groups showed a significant decrease in FPG and HbA1c after treatment (P＜0.05). Compared with the control group, FPG ［(6.96±0.87) mmol/L vs (7.91±0.96) mmol/L, t=4.083, P＜0.01］ and HbA1c ［(6.54±0.33)% vs (7.65±0.58)%, t=9.261, P＜0.01］ of patients in the observation group were significantly decreased, and the standard deviation of mean blood glucose (SDBG) and amplitude of postprandial blood glucose fluctuation (PPGE) were lower (P<0.05), CRP was lower and LVEF was higher (P<0.05) in the observation group compared to the control group. Conclusion Dapagliflozin combined with sitagliptin has a significant effect in the treatment of T2DM. It can effectively reduce the level of blood glucose, reduce the occurrence of hypoglycemia, and improve the inflammatory reaction and cardiac function of patients.
Keywords
